Tags : Research

MSD Signs a Research and Option to License Agreement with

Shots: 4D to receive up front in cash for each indication, ~$347.5M as option exercise fee, development & commercialization milestones with royalties on sales of licensed product derived from the collaboration. 4D has rights to cause MSD to purchase 4D shares for $5M during the first 12 mos. of the collaboration The agreement will combine […]Read More

Eisai Signs a Research and Option Agreement with Numab to

Shots: Numab to receive up front, research funding, success fees, milestones & royalties on sales. Eisai to get an option to acquire an exclusive license to develop and commercialize novel multi-specific antibody-based molecules developed utilizing Numab’s MATCH platform The focus of the agreement is to leverage Numab’s multi-specific technology to generate cancer therapies providing superior […]Read More

Novartis Signs an Exclusive Research and Option to Acquire Agreement

Shots: Novartis to get an option to acquire IFM Due (a subsidiary of IFM Therapeutics) in exchange of funding for research & development of cGAS/STING program. Post exercising of option, IFM to receive $840M including up front and other contingent consideration IFM has two preclinical pipeline programs, first developing as oral STING antagonist having the […]Read More

MSD Signs an Exclusive License and Research Agreement with Themis

Shots: MSD enters into a research collaboration and exclusive license agreement for the discovery and development of undisclosed vaccine candidates utilizing Themis’ measles virus vector-based platform Themis to receive ~200M development and commercial milestones and royalties on approved products from the agreement. MSD to provide research funding and make an equity investment in Themis Themis […]Read More

Takeda Signs an Exclusive Multi-Target Research Agreement with Sosei Heptares

Shots: Sosei Heptares to receive $26M up front, R&D funding, $1.2B+ development & commercial milestones and royalties on sales of the licensed products. Takeda to get WW rights to develop & commercialize therapies for each target through specified pharmacological approaches in the collaboration The focus of the agreement is to develop multiple GPCR targets nominated […]Read More

Genentech Signs a Research and License Agreement with Sosei Heptares

Shots: Sosei Heptares to receive $26M as up front and near-term payment, up to $1B as research, development and commercialization milestones and royalties on sales. Genentech to get exclusive WW rights to develop & commercialize therapies for each novel target  The focus of the agreement is to combine Sosei Heptares’ GPCR-focused structure-based drug design capabilities […]Read More

Immunophotonics Signs a Research Agreement with Clinical Laserthermia Clinical Laserthermia

Shots: Immunophotonics and CLS collaborate to evaluate the safety & tolerability of Immunophotonics’ IP-001 in P-Ib/IIa study for cancer patients with solid tumors The collaboration will combine CLS’ Immunostimulating Interstitial Laser Thermotherapy (imILT) method & TRANBERG Laser Thermal Therapy System with an intra-tumoral injection of IP-001   Immunophotonics’ IP-001 is designed to be injected intratumorally […]Read More

Bayer Signs a Research and Development Collaboration with Arvinas for

Shots: Arvinas to get ~$60M including upfront, equity investments, R&D funds and $685M milestones and royalties on sales of products. Bayer to get rights for the therapies developed in collaboration using Arvinas’s PROTAC Technology The focus of the collaboration is to develop therapies using Arvinas’ PROTAC protein degrader technology in cardiovascular, oncology, and gynecological disorders […]Read More

Abbott Collaborates with NIH on Brain Initiative for Advancing Research

Shots: Abbott to provide its neuromodulation technologies including deep brain stimulation (DBS), spinal cord stimulation (SCS), and dorsal root ganglion (DRG) therapy. NIH to utilize Abbott’s technology for exploring its applications in chronic pain and progressive movement disorders as Parkinson’s disease The focus of the collaboration is to accelerate the application of Abbott’s neurostimulation therapies, […]Read More